(Total Views: 758)
Posted On: 10/28/2020 6:14:15 PM
Post# of 154140
Only 6.5% of the placebo patients in today's Regeneron study ever had a follow-up medical visit - even tele-health.
Cutting that to 2.8% sounds great, but it means you have to treat 27 people to keep 1 from that next visit.
What fraction of those with a next visit would die? A few percent? So you have to treat 500 - 1,000 people to save one life?
So Regeneron is a big winner in a population that can't sensibly use it. Obviously, subgroups matter - their "high titer" group is akin to CD10's "score>=4" group, and may be a more plausible treatment target.
Even with that, the trial of the sickest (CD12) also becomes the trial of what's the most effective use of limited-availability medication.
Cutting that to 2.8% sounds great, but it means you have to treat 27 people to keep 1 from that next visit.
What fraction of those with a next visit would die? A few percent? So you have to treat 500 - 1,000 people to save one life?
So Regeneron is a big winner in a population that can't sensibly use it. Obviously, subgroups matter - their "high titer" group is akin to CD10's "score>=4" group, and may be a more plausible treatment target.
Even with that, the trial of the sickest (CD12) also becomes the trial of what's the most effective use of limited-availability medication.
(3)
(0)
